1. Home
  2. IIF vs ELTX Comparison

IIF vs ELTX Comparison

Compare IIF & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Morgan Stanley India Investment Fund Inc.

IIF

Morgan Stanley India Investment Fund Inc.

HOLD

Current Price

$22.95

Market Cap

210.5M

Sector

Finance

ML Signal

HOLD

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$2.80

Market Cap

185.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IIF
ELTX
Founded
1993
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
210.5M
185.4M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
IIF
ELTX
Price
$22.95
$2.80
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$18.00
AVG Volume (30 Days)
33.3K
877.0K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
13.94%
N/A
EPS Growth
N/A
39.29
EPS
N/A
N/A
Revenue
N/A
$2,301,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$19.83
$2.66
52 Week High
$27.99
$16.00

Technical Indicators

Market Signals
Indicator
IIF
ELTX
Relative Strength Index (RSI) 57.41 34.75
Support Level $22.01 $2.72
Resistance Level $23.66 $5.38
Average True Range (ATR) 0.42 0.22
MACD -0.01 0.21
Stochastic Oscillator 73.11 20.31

Price Performance

Historical Comparison
IIF
ELTX

About IIF Morgan Stanley India Investment Fund Inc.

Morgan Stanley India Investment Fund, Inc. is the United States based non-diversified, closed-end management investment company. Its investment objective is to achieve long-term capital appreciation through investment in equity securities of Indian Issuers. The company's portfolio of investments consists of the investment in different sectors such as auto components, banks, capital markets, construction and engineering, pharmaceuticals and others.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Share on Social Networks: